India’s PharmNXT Biotech targets the global bioprocessing market with cost-effective innovation
As global demand for biologics rises, pharmaceutical manufacturing is undergoing a structural shift. Biologic drugs, including monoclonal antibodies, vaccines, and advanced therapies, are expected to account for nearly 35–40 percent of the global pharmaceuticals market by 2030, according to IQVIA. At the same time, rising costs in the United States and Europe, along with supply disruptions during the COVID-19 pandemic, have accelerated the need for more diversified and resilient manufacturing ecosystems.
How Emerging Biotech Startups Reshaping the Bioprocessing Future
In an interaction with Thiruamuthan, Assistant Editor of India Pharma Outlook, Ankush Kapoor, Founder & CEO of PharmNXT Biotech, discusses how India’s biotech ecosystem is redefining bioprocessing through Single-Use Technologies, Defined Tubing Routing, and digital innovation. These advancements are enhancing scalability, sustainability, and compliance while significantly reducing energy, water use, and contamination risks. Startups are increasingly adopting modular, AI-driven, and continuous systems to overcome resource constraints, advance cell and gene therapy production, and position India as a global hub for efficient, sustainable, and technologically advanced biomanufacturing.
Pharma Industrial India Magazine – September – October
Pharma Industrial India Magazine – September – October
PharmNXT Acquires DTR to Bring European Bioprocess Manufacturing Expertise to India
In a major boost to India’s biopharmaceutical manufacturing landscape, Pune-based startup PharmNXT Biotech has acquired Ireland-based Defined Tubing Routing (DTR), a globally recognised innovator in advanced bioprocess tubing solutions. The strategic acquisition gives PharmNXT direct access to cutting-edge technology in single-use systems, significantly enhancing its ability to deliver customised, high-compliance solutions for pharmaceutical and biopharma clients.
PharmNXT acquires DTR, brings European bioprocess engineering to India
PharmNXT Biotech has acquired Defined Tubing Routing (DTR), a player from Ireland, working in advanced bioprocess tubing solutions. This move enables PharmNXT to access technology solutions related to single-use systems. With the addition of DTR’s modular tubing systems, capable of supporting bioprocess volumes from 20 L to 500 L and custom spans up to 2.9 meters, PharmNXT expands its engineering capabilities, faster turnaround, enhanced customisation, and stronger compliance.
PharmNXT brings European Bioprocess Engineering to India with strategic acquisition of DTR
This move enables PharmNXT to access technology solutions related to single-use systems, strengthening its capacity to serve pharmaceutical and biopharma clients with more tailored and technically aligned offerings. With the addition of DTR’s modular tubing systems, capable of supporting bioprocess volumes from 20 L to 500 L and custom spans up to 2.9 meters, PharmNXT significantly expands its engineering capabilities, faster turnaround, enhanced customisation, and stronger compliance.
PharmNXT Brings European Bioprocess Engineering to India with Strategic DTR Acquisition
In a landmark development for India’s biopharmaceutical sector, PharmNXT Biotech has acquired Defined Tubing Routing (DTR), a globally recognised player from Ireland, working in advanced bioprocess tubing solutions. This move enables PharmNXT to access technology solutions related to single-use systems, strengthening its capacity to serve pharmaceutical and biopharma clients with more tailored and technically aligned offerings.
How a Mumbai startup stepped up during Covid to disrupt the global biopharma supply chain
As the Covid-19 pandemic swept across the globe, Indian vaccine makers faced an unexpected bottleneck—not in science or manpower, but in consumables. The single-use bags made of specialised plastic required for mixing and storing vaccine ingredients were in critically short supply.
Driving Innovation and Localized Manufacturing: A Vision for the Future of Biopharma with PharmNXT Biotech
In an exclusive interview with Mr. Ankush Kapoor, Founder and CEO, and Mr. Sachin Joshi, Managing Director & Founder of PharmNXT Biotech, we explore the company’s remarkable journey in revolutionizing biopharma.
Union Budget 2025 lays emphasis on cancer care, medical education & innovation
Union Minister of Finance and Corporate Affairs Nirmala Sitharaman presented the Union Budget 2025-26 in Parliament today, 1 February 2025. Laying emphasis on improving cancer care and treatment for millions in the country, the government has decided to set up Day Care Cancer Centres in all district hospitals in the next 3 years, with 200 centres coming up in 2025-26.